33 results about "Antigen response" patented technology

The present disclosure concerns immunomodulatory compositions and methods of use for enhancing response to an antigen (e.g., in a vaccine), an immunotherapy (e.g., a cancer immunotherapy), or other immune stimulation. The disclosure describes immunomodulators having reduced toxicity and improved immune response compared with existing adjuvants. Further disclosed are methods for improving an immune response to a vaccine antigen, cancer immunotherapeutic, or other immune stimulating agent. The disclosure describes dimeric and polymeric immunomodulators comprising one or more pattern recognition receptor (PRR) agonist moieties and one or more NF-κB inhibitor moieties.

The present invention relates to chimeric co-stimulatory antigen receptors (CoStAR) useful in adoptive cell therapy (ACT) and cells comprising said CoStAR. CoStAR can be used as modulators that enhance the activity of cells that respond to determined antigens. The invention also provides CoStAR proteins, nucleic acids encoding said CoStAR, and therapeutic uses thereof.

The invention discloses a microsphere coating method, an immunochromatography detection kit and a preparation method and application of the kit, and the microsphere coating method comprises the following steps: S1, preparing microspheres for marking antigens and antibodies to be detected and microspheres for marking quality control antibodies; and S2, coating the microspheres marked with the to-be-detected antigens and the to-be-detected antibodies and the microspheres marked with the quality control antibodies in the step S1 in a customized gun head or a reaction cup. Compared with the prior art, the antibody-labeled microsphere compound and the to-be-detected sample antigen are subjected to a more efficient reaction in advance, the problem of sufficiency of the reaction between the antibody-labeled microsphere and the to-be-detected antigen is thoroughly solved, the competition efficiency is improved, and the detection result is more accurate; moreover, the labeled antibody microspheres are solid reagents, can be directly used, and are high in sensitivity, high in accuracy, good in stability, wide in linear range and long in storage time, and the storage condition does not need refrigeration.

The present disclosure provides methods for identifying T-cell receptors (TCRs) from sequencing data, and TCR sequences identified using the methods. The methods can comprise identifying a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain from the sequencing data, and then identifying the corresponding paired chain. The "de novo" method can comprise the identification of statistically associated TCR chain sequences by assessing patients' antigenic status and / or HLA alleles. In the "bait" method, a TCR chain sequence of a TCR known to have some degree of antigen reactivity can be used to search for related sequences in the large database. Resulting sequences may or may not exhibit statistical enrichments that can be detected using the "de novo" approach. Various pairing methods are provided. Identified paired TCR chains can be used for preparing various therapies including cell-based therapies.

Provided herein are CasX:gNA systems, and compositions and methods relating thereto, the systems comprising CasX proteins, guide nucleic acids (gNAs), and optionally donor template nucleic acids useful for the modification cell genes encoding proteins involved in antigen processing, antigen presentation, antigen recognition, and / or antigen response, as well as methods of producing and using populations of cells comprising these modified genes. In some embodiments, the modified cells further express chimeric antigen receptors (CAR) or engineered T cell receptors (TCR). Such systems are useful for preparing cells for immunotherapy.

An antibody for use in an immunoassay method, the antibody comprising an Fc region, wherein at least part of a glycan comprised in the Fc region has been removed.

The invention provides a multi-index test strip which sequentially comprises a sample pad, a combination pad, a reaction film and an absorption pad in the flowing direction of a sample, the combination pad comprises a first fluorescent microsphere-labeled antibody and a second fluorescent microsphere-labeled antibody, the first fluorescent microsphere-labeled antibody is combined with a first antigen, and the second fluorescent microsphere-labeled antibody is combined with a second antigen; a detection line and a quality control line are sequentially arranged on the reaction film in the sample flowing direction, and the detection line comprises a first capture antibody paired with the antibody marked by the first fluorescent microsphere and a second capture antibody paired with the antibody marked by the second fluorescent microsphere; wherein the first antigen in the sample to be detected is more difficult to detect than the second antigen, and the particle size of the first fluorescent microspheres is smaller than that of the second fluorescent microspheres. According to the multi-index test strip, the sensitivity and specificity during multi-index detection can be improved, mutual interference during multi-index detection can be reduced, the linear range and correlation can be improved, and the detection cost cannot be remarkably increased.

The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.

To provide an antigen responsiveness enhancer. [Solution] From Euglena, paramylon, paramylon processed product, and β-1,3-glucan An antigen response enhancer containing at least one selected from the group.

A system and method for diagnosing traumatic brain injury (TBI) includes a proteome biochip including a set of brain protein fractions including primary serum autoantibodies reactive with brain protein autoantigens released by the TBI printed into micro-wells of a glass slide. The biochip hybridized with non-TBI and TBI-injured serum samples from which an autoantibody response profile is generated. The system additionally including labeled IgG or IgM secondary antibodies for addition to the micro-wells for binding with one of the primary serum autoantibodies, a side illumination laser to read the micro-wells in which the labeled IgG or IgM secondary antibodies are bound with one of the primary serum autoantibodies, and a readout detection system for the set of brain protein fractions to screen for autoantigens present in the micro-wells that contain the labeled IgG or IgM secondary antibodies bound with one of the primary serum autoantibodies to generate a heat map.

The invention provides a nano vaccine vector based on cholesteroid-free capsule protein and application of the nano vaccine vector, and belongs to the technical field of nano particle vaccines. The nano vaccine carrier is formed by sequentially connecting cholesteroid-free capsule protein, extension peptide, linker and molecular glue from an N end to a C end. The invention also provides a nano vaccine based on the cholesteric plasma-free capsule protein. The antigen is obtained by reacting the carrier with an antigen connected with SpyTag, SpyTag002 or SpyTag003. The invention also provides a mycoplasma hyopneumoniae nano vaccine and a new crown nano vaccine. The antigen is obtained by reacting the carrier with an antigen connected with SpyTag003. The nano vaccine vector disclosed by the invention can be used for intramuscular injection vaccines and mucosal vaccines for human and livestock, can remarkably improve the immune effect and enhance the immune response while displaying antigens, has a remarkable self-adjuvant effect, and provides a safe and efficient potential choice for the development of subunit vaccines.

The present invention discloses a method for evaluating the virus adsorption capacity of a purified filler, wherein the filler is mixed with a virus liquid to adsorb the virus onto the filler; after cleaning the filler, animal serum containing antiviral antibodies is added to react with the antigen on the filler; after cleaning the filler, an anti-animal serum enzyme-labeled secondary antibody is added to react with the antigen on the filler; after cleaning the filler, a display liquid is added to perform a color reaction; after the color reaction is completed, the supernatant is taken after centrifugation and added to a 96-well plate, and an ELISA is used to calculate the absorbance OD of each well at a wavelength of 450nm, and the antigen adsorption capacity of the filler is evaluated by the OD value. Compared with the prior art, the present invention provides a basis for screening fillers for virus purification by fixing the antigen on the filler and applying the indirect ELISA method to detect the antigen fixing capacity of different fillers, and has the advantages of low cost, low technical threshold and fast reaction.

The application discloses a chicken interleukin 2 antibody and application thereof, the antibody comprises a light chain and a heavy chain variable region, the amino acid sequences of three complementarity determining regions in the light chain variable region are respectively shown as SEQ ID NO. 1-3, the amino acid sequences of three complementarity determining regions in the heavy chain variable region are respectively shown as SEQ ID NO. 5-7, or the amino acid sequences of three complementarity determining regions in the light chain variable region are respectively shown as SEQ ID NO. 17-19, and the amino acid sequences of three complementarity determining regions in the heavy chain variable region are respectively shown as SEQ ID NO. 21-23. The antibody provided by the application has the advantages of high effective value, good specificity, high affinity and reaction with natural ChIL-2 antigen. The ChIL-2 double antibody sandwich enzyme-linked immunosorbent assay (ELISA) established based on the two antibodies has the advantages of high specificity, high sensitivity, simple operation and good repeatability, and can be used for determination of the ChIL-2 content in cell culture supernatant, chicken serum and other samples.

The invention discloses denatured IgG for determining rheumatoid factors, a preparation method of the denatured IgG, a detection reagent and a kit, and relates to the technical field of rheumatoid factor detection. The preparation method of the denatured IgG for measuring the rheumatoid factors comprises the following steps: carrying out thermal denaturation treatment on IgG to obtain first denatured IgG; mixing the first denatured IgG with basic amino acid to obtain second denatured IgG; mixing the second denatured IgG with a denaturant to obtain third denatured IgG; and mixing the third denatured IgG with a cross-linking agent, and carrying out a cross-linking reaction to obtain the denatured IgG for measuring rheumatoid factors. According to the present invention, the antigen epitope is completely exposed, and the antigen reaction activity is enhanced, such that the RF detection sensitivity is improved, the linear range is widened, and the HOOK ability is improved.

The present invention discloses a fusion protein of Fel D1 and Fel D4 and its application. The present invention obtains the fusion protein of Fel D1 and Fel D4 by prokaryotic expression. The fusion expressed protein greatly simplifies the operation procedures in terms of inducing protein expression, purification, concentration and immunization, and reduces the economic cost. The present invention provides a method for preparing egg yolk antibodies. The egg yolk antibodies obtained by immunizing laying hens with fusion proteins can react with Fel D1 and Fel D4 respectively, and the titer is higher than that of a single antigen protein immunization group and a combined immunization group. The present invention also provides a method for preparing a functional cat food. Egg yolk powder is added to the cat food in a certain proportion. After feeding for a period of time, the content of Fel D1 and Fel D4 in the cat's hair and saliva is significantly reduced, and the cat food prepared by the fusion protein egg yolk antibody can resist Fel D1 and Fel D4 at the same time, and the blocking effect is significantly improved.

The present disclosure is directed to the accurate and high throughput method for screening and identifying antigen-reactive T Cell Receptors (TCRs) capable of triggering effective T-cell activation.

The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.

According to the present disclosure, there is provided a method of producing an immune cell that responds to a cancer-associated antigen, the method including stimulating an immune cell with an antigen contained in a pluripotent stem cell. In addition, according to the present disclosure, there is provided a method of producing an immune cell that responds to a cancer-associated antigen, the method including stimulating an immune cell with at least part of a pluripotent stem cell. In addition, according to the present disclosure, there is provided a method of amplifying response of an immune cell to a cancer-associated antigen, the method including stimulating an immune cell with an antigen contained in a pluripotent stem cell. In addition, according to the present disclosure, there is provided a method of amplifying response of an immune cell to a cancer-associated antigen, the method including stimulating an immune cell with a pluripotent stem cell.

The present invention relates to compositions for detecting a lung cancer disease, comprising peptide affinity ligands for detecting different combinations of proteins of different groups of biomarkers which include CYFRA 21-1, Prolactin, Squamous Cell Carcinoma Antigen (SCC), Her2 / Neu, Cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), C- reactive protein (CRP), Neuron Specific Enolase (NSE), C4 complement (C4), Interleukin 6 (IL-6), and Metallopeptidase Inhibitor 1 (TIMP-1). The invention further relates to methods of detecting or subtyping lung diseases, as well as to computer-implemented methods based on machine learning methods using expression data of the biomarkers.

This invention relates to a genetically engineered bacterial outer membrane vesicle and its preparation method. By using in-cell peptides to attach exogenous proteins to the surface of OMVs via peptide bonds, a variety of desired antigens can be conveniently delivered. The reaction conditions are mild, less affected by antigen size, and unlike the SpyCatcher / SpyTag system, the in-cell peptides do not remain in the mature protein after attaching the exogenous protein to the OMV surface. This invention can serve as a universal tool for simultaneously or separately displaying different antigens on the surface of OMVs.

The present disclosure provides methods for identifying T-cell receptors (TCRs) from sequencing data. The methods can comprise identifying a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain from the sequencing data, and then identifying the corresponding paired chain. The "de novo" method can comprise the identification of statistically associated TCR chain sequences by assessing patients' antigenic status and / or HLA alleles. In the "bait" method, a TCR chain sequence of a TCR known to have some degree of antigen reactivity can be used to search for related sequences in the large database. Resulting sequences may or may not exhibit statistical enrichments that can be detected using the "de novo" approach. Various pairing methods are provided. Identified paired TCR chains can be used for cell-based therapies.

This invention relates to the field of tumor vaccines, specifically to an anti-tumor vaccine, its preparation method, and its application. The invention prepares an anti-tumor vaccine, BCG-CW@LNT, by mixing cell walls extracted from BCG vaccine as an immune adjuvant with LNT cells obtained from tumor cells through rapid freeze-thaw cycles in liquid nitrogen. This vaccine utilizes these "therapeutic dead cells" to induce a broad antigen response throughout the entire cell, mimicking the natural presentation of antigens in the tumor microenvironment, thereby enhancing anti-cancer immunity. In bladder cancer and lung cancer models, BCG-CW@LNT demonstrated good anti-tumor therapeutic effects. Furthermore, due to the presence of memory T cells, it exhibits a long-term memory effect, providing long-term anti-tumor and preventative effects, effectively preventing tumor recurrence and offering a novel option for tumor treatment.

Various embodiments of the invention provide compositions of tumor infiltrating lymphocytes (TILs) enriched in tumor reactive cells, methods for manufacturing TILs enriched in tumor reactive cells and methods and uses of the provided enriched tumor reactive TILs for treating cancer in a human or other subject. Among the provided embodiments of TIL compositions may include those that exhibit substantial tumor reactivity activity, including degranulation and the ability to express one or more of IFN-gamma and TNF-alpha, in response to antigen presenting cells presenting neo antigenic peptides.

To provide high-throughput methods to screen cognate T cell and epitope reactivities in primary human cells.SOLUTION: Described is an autologous primary immune cell assay in which an individual's own blood cells may be functionally screened against individual antigens, e.g., T cell epitopes, of interest without the use of HLA haplotype-specific reagent. Antigen reactivities are linked to individual T cells using an oligonucleotide-tagging hashing tracking system, which is later deconvolved by single cell sequencing.SELECTED DRAWING: None

The present disclosure provides methods for identifying T-cell receptors (TCRs) from sequencing data. The methods can comprise identifying a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain from the sequencing data, and then identifying the corresponding paired chain. The "de novo" method can comprise the identification of statistically associated TCR chain sequences by assessing patients' antigenic status and / or HLA alleles. In the "bait" method, a TCR chain sequence of a TCR known to have some degree of antigen reactivity can be used to search for related sequences in the large database. Resulting sequences may or may not exhibit statistical enrichments that can be detected using the "de novo" approach. Various pairing methods are provided. Identified paired TCR chains can be used for cell-based therapies.

Various aspects of the present invention provide compositions of tumor-infiltrating lymphocytes (TILs) enriched for tumor-reactive cells, methods for producing TILs enriched for tumor-reactive cells, and methods and uses of the provided enriched tumor-reactive TILs for treating cancer in humans or other subjects. Among the provided aspects of the TIL compositions can be TIL compositions that exhibit substantial tumor-reactive activity, including degranulation and the ability to express one or more of IFN-γ and TNF-α in response to antigen-presenting cells that present neo-antigenic peptides. TIFF2025537148000002.tif51170

The present invention discloses tumor antigen peptides targeting CD73, vaccines, and preparation methods and applications thereof. Based on the amino acid sequence of CD73 protein, the present invention combines MHC typing to synthesize antigen peptides for targeted and immunotherapy of solid tumors, including drugs and vaccines for the preparation of new antigen-reactive T cell therapy and engineered T cell therapy. The tumor peptide vaccine targeting CD73 provided by the present invention has good immunogenicity and strong targeted killing ability of induced antigen-specific T cells.

The present invention provides a polypeptide molecule comprising n copies of peptide monomers, where n is any integer from 2 to 14. According to the present invention, a certain number of multi-copy target sequences are repeatedly inserted in a single expression region to obtain the complex formed by connecting a plurality of monomer proteins (polypeptides); the stability of the obtained multi-copy protein (polypeptide) is obviously superior to that of a single-copy protein (polypeptide). The stability is improved, and meanwhile, no allogenic material is introduced. And the antigen reactivity of the protein (polypeptide) is not influenced. The method can be used for storing polypeptide or protein in a non-freeze-drying mode and preparing a liquid polypeptide quality control substance with good stability.

Disclosed is a method of providing antigen-reactive lymphocytes comprising: (a) obtaining lymphocytes of an individual wherein the individual carries at least one antigen; (b) establishing a primary culture of lymphocytes; (c) introducing a transient reporter system into the lymphocytes of the primary culture, wherein the reporter system generates a signal upon activating the nuclear translocation of the T cell nuclear factor (NFAT); (d) attacking the lymphocytes with at least one antigen; and (e) screening at least one antigen-reactive lymphocyte from the lymphocytes by detecting the signal. Also disclosed are pharmaceutical compositions comprising amplified antigen-reactive lymphocytes obtained by the method and kits for performing the method.

The invention relates to the field of tumor vaccines, in particular to an anti-tumor vaccine as well as a preparation method and application thereof. The anti-tumor vaccine BCG-CW-LNT is prepared by taking cell walls extracted from BCG as immunologic adjuvants and then mixing the cell walls with LNT cells obtained by quickly freezing and thawing tumor cells through liquid nitrogen. According to the vaccine, the therapeutic dead cells can be utilized, wide antigen reactions are initiated through whole cells, and natural presentation of antigens in a tumor microenvironment is simulated, so that the anti-cancer immunity is enhanced. In bladder cancer and lung cancer models, the BCG-CW-LNT shows a good anti-tumor treatment effect, has a long-term memory effect due to the existence of memory T cells, can provide long-term anti-tumor and prevention effects, can effectively prevent tumor recurrence, and provides a brand new choice for tumor treatment.